Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
GSK Stock Chart & Stats
Day’s Range― - ―
52-Week Range1,242.50p - 1,649.25p
Previous CloseN/A
Volume367.08K
Average Volume (3M)6.75M
Market Cap
£61.10B
Enterprise Value73.93B
Total Cash (Recent Filing)£3.62B
Total Debt (Recent Filing)£17.35B
Price to Earnings (P/E)18.1
Beta0.85
Next Earnings
Oct 29, 2025EPS Estimate
0.47Last Dividend Ex-Date
Aug 14, 2025Dividend Yield3.9%
Share Statistics
EPS (TTM)0.45
Shares Outstanding4,069,035,200
10 Day Avg. Volume6,111,672
30 Day Avg. Volume6,748,878
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£1,582.83Price Target Upside5.28% Upside
Rating ConsensusHold
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Stock ValuationGSK is characterized by low price-to-earnings ratios, offering a potentially attractive entry point for investors despite the challenges.
Bears Say
Competitive PressuresUncertainty exists about whether future product launches, such as depemokimab, can compensate for current challenges and competitive pressures.
Earnings OutlookGSK has one of the lowest P/E ratios in the sector, but it also has the worst projected EPS growth rate from 2027 to 2030, indicating slowing performance.
Foreign Exchange RisksForeign exchange impacts are expected to worsen, offsetting guidance improvements and affecting sales and operating profit.
Product Launch ChallengesConcerns exist over the delayed approval process for Blenrep, a key launch for GSK, due to negative advisory committee feedback and the submission of additional data.
R&D And Earnings ImpactHigher R&D spending is anticipated to negatively impact future earnings per share.
GlaxoSmithKline News
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1242.50p and its highest was 1649.25p in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is £61.10B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Oct 29, 2025 which is in 45 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Apr 30, 2025. The company reported 0.449p earnings per share for the quarter, beating the consensus estimate of 0.4p by 0.049p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Quarterly dividend of 16p which represents an annual dividend yield of 3.9%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 0.47.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,069,035,200 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.449p in its last earnings report, beating expectations of 0.4p. Following the earnings report the stock price went up 3.597%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
GlaxoSmithKline Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
£1,582.83 (5.28% Upside)
£1,582.83 (5.28% Upside)
Insider Transactions
Sold Shares
Worth £459.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.98%
12-Months-Change
Fundamentals
Return on Equity
23.47%
Trailing 12-Months
Asset Growth
2.05%
Trailing 12-Months
Company Description
GlaxoSmithKline
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
GSK Stock 12 Month Forecast
Average Price Target
1,582.83p
▲(5.28% Upside)
Technical Analysis
AstraZeneca
―
ConvaTec
―
Hikma Pharmaceuticals
―
Smith & Nephew
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---